Further Information
HDMX, hdm2, ACTFS, ESA1, M17S1,
Western Blot: 1:500~1:1000, Immunohistochemistry: 1:50~1:100, Immunofluorescence: 1:100~1:200
This gene is a target gene of the transcription factor tumor protein p53. The encoded protein is a nuclear phosphoprotein that binds and inhibits transactivation by tumor protein p53, as part of an autoregulatory negative feedback loop. Overexpression of this gene can result in excessive inactivation of tumor protein p53, diminishing its tumor suppressor function. This protein has E3 ubiquitin ligase activity, which targets tumor protein p53 for proteasomal degradation. This protein also affects the cell cycle, apoptosis, and tumorigenesis through interactions with other proteins, including retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants have been isolated from both tumor and normal tissues
- Haupt, Y. et al. (1997) Nature 387, 296-299. Zhou, B. P. et al. (2001) Nat. Cell Biol. 3, 973-981. Grossman, S. R. et al. (1998) Mol. Cell 2, 405-415. Mayo, L. D. and Donner, D. B. (2001) Proc. Natl. Acad. Sci. USA 98, 11598-11603.
Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
1 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
MDM2 (phospho-Ser166) antibody was raised against a peptide sequence around phosphorylation site of Serine 166 (A-I-S (p) -E-T) derived from Human MDM2.
Phospho-Specific
4193
MDM2 oncogene, E3 ubiquitin protein ligase
MDM2
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
90 kDa
NP_002383.2
89993689
Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.
Phospho-Specific
This antibody detects endogenous level of MDM2 only when phosphorylated at serine 166.
Q00987